Deep dives into the evidence behind peptides, supplements, and protocols. Every claim graded, every gap named.
We tested every peptide tracker app in 2026. Here's what we found, including where our competitors beat us.
The peptide tracker market went from empty to 15+ apps in 12 months. We tested them all and scored them on what matters: safety features, PK modelling, multi-compound support, and price. Pinned is ours. We're transparent about that.
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
You're spending $200–500/month on biological software and tracking it in a Notes app. The compounds aren't the problem. The total absence of protocol discipline is.
Peptide access exploded in 2026. Protocol discipline didn't follow. Most users are dosing from Reddit consensus, ignoring half-lives, missing timing windows, and running zero safety baselines. This article maps the specific failure modes, the insulin trap, the NO floor, the receptor ceiling, the sedentary trap, and what precision tracking actually looks like by comparison.
Two sister peptides from the same Cold War lab, one calms the emotional floor, the other raises the cognitive ceiling. The mechanistic case for stacking them is architecturally compelling. The clinical evidence for the combination doesn't exist yet.
Selank and Semax are sister heptapeptides engineered with the same glyproline stability tail but from opposite parent molecules, tuftsin (immune) and ACTH (stress). They converge on BDNF through completely different upstream pathways, covering complementary neurochemical territory. This article examines the mechanistic case for combining them, the cofactors that determine whether either signal lands, and where the evidence stops short.
Fixed-ratio peptide blends promise synergy in a single vial — but pharmacokinetics, missing human data, and one-size-fits-all dosing tell a different story.
From BPC/TB duos to quad stacks, we examine why pre-mixed peptide blends fail the precision medicine test — mismatched half-lives, untested combinations, and the convenience tax you're actually paying.
A research-driven breakdown of what's actually inside the most popular peptide blend — and why fixed ratios create pharmacological problems your supplier won't mention.
Inside the KLOW quad stack: GHK-Cu, BPC-157, TB-500, and KPV. We examine the pharmacokinetic mismatches, the missing human trials, and why individual titration beats fixed-ratio convenience.
Peptides send the signal — but without the right micronutrient partners, the instruction falls flat. Here's the biochemistry behind why your protocol needs more than peptides.
Evidence-graded analysis of the micronutrient co-factors that determine whether peptide therapy delivers results — from Vitamin C and collagen synthesis to zinc and the IGF-1 axis, plus the contested evidence and research gaps the field still needs to close.